Author:
Chandna Arjun,Lubell Yoel,Mwandigha Lazaro,Tanunchai Phattaranit,Vinitsorn Asama,Richard-Greenblatt Melissa,Koshiaris Constantinos,Limmathurotsakul Direk,Nosten Francois,Abdad Mohammad Yazid,Perera-Salazar Rafael,Turner Claudia,Turner Paul
Abstract
AbstractReliable tools to inform outpatient management of childhood pneumonia in resource-limited settings are needed. We investigated the value added by biomarkers of the host infection response to the performance of the Liverpool quick Sequential Organ Failure Assessment score (LqSOFA), for triage of children presenting with pneumonia to a primary care clinic in a refugee camp on the Thailand-Myanmar border. 900 consecutive presentations of children aged ≤ 24 months meeting WHO pneumonia criteria were included. The primary outcome was receipt of supplemental oxygen. We compared discrimination of a clinical risk score (LqSOFA) to markers of endothelial injury (Ang-1, Ang-2, sFlt-1), immune activation (CHI3L1, IP-10, IL-1ra, IL-6, IL-8, IL-10, sTNFR-1, sTREM-1), and inflammation (CRP, PCT), and quantified the net benefit of including biomarkers alongside LqSOFA. We evaluated the differential contribution of LqSOFA and host biomarkers to the diagnosis and prognosis of pneumonia severity. 49/900 (5.4%) presentations met the primary outcome. Discrimination of LqSOFA and Ang-2, the best performing biomarker, were comparable (AUC 0.82 [95% CI 0.76–0.88] and 0.81 [95% CI 0.74–0.87] respectively). Combining Ang-2 with LqSOFA improved discrimination (AUC 0.91; 95% CI 0.87–0.94; p < 0.001), and resulted in greater net benefit, with 10–30% fewer children who required oxygen supplementation incorrectly identified as safe for community-based management. Ang-2 had greater prognostic utility than LqSOFA to identify children requiring supplemental oxygen later in their illness course. Combining Ang-2 and LqSOFA could guide referrals of childhood pneumonia from resource-limited community settings. Further work on test development and integration into patient triage is required.
Publisher
Springer Science and Business Media LLC
Reference59 articles.
1. Lodha, R., Kabra, S. K. & Pandey, R. M. Antibiotics for community-acquired pneumonia in children. Cochrane Database Syst. Rev. 6, CD004874 (2013).
2. Wilkes, C., Graham, H., Walker, P., Duke, T., Group ARIR. Which children with chest-indrawing pneumonia can be safely treated at home, and under what conditions is it safe to do so? A systematic review of evidence from low- and middle-income countries. J. Glob. Health 12, 10008 (2022).
3. Zhang, S. et al. Cost of management of severe pneumonia in young children: Systematic analysis. J. Glob. Health 6(1), 010408 (2016).
4. Marangu, D. & Zar, H. J. Childhood pneumonia in low-and-middle-income countries: An update. Paediatr. Respir. Rev. 32, 3–9 (2019).
5. McAllister, D. A. et al. Global, regional, and national estimates of pneumonia morbidity and mortality in children younger than 5 years between 2000 and 2015: A systematic analysis. Lancet Glob. Health 7(1), e47–e57 (2019).